MedTrace Logo

A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

NCT06666283 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2025-09-11

No results posted yet for this study

Summary

The study will be a single center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, PK and PD of AP303 following 2-week oral administration to Diabetic Kidney Disease patients.

Conditions

  • Diabetic Kidney Disease

Interventions

DRUG

AP303 150μg

AP303 Tablet 150μg QD

DRUG

Placebo 150μg

Placebo Tablet 150μg QD

Sponsors & Collaborators

  • Alebund Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Hong Zhang · Peking University First Hospital

  • Ying Gao · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-27
Primary Completion
2025-09-25
Completion
2025-09-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06666283 on ClinicalTrials.gov